VHH as Agonists & Antagonists
Antagonist/agonist VHH antibodies have the ability to modulate the activity of the signalling pathways, making them potentially useful in the treatment of many diseases.
VHH as Agonists & Antagonists Resources
Isogenica’s PD-L1 VHH as
OCTOBER 13, 2021
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. The interaction between PD-1 and PD-L1 can be both beneficial and harmful…
Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
APRIL 26, 2021
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery…
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.